U.S. Online Retail and Ecommerce Stock News

NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Wide Valuation Range After Recent Volatility

If you are wondering whether Recursion Pharmaceuticals at around US$3.39 is a bargain or a value trap, this article breaks down what the current share price might be telling you. The stock has been volatile, with a 3.4% decline over the last week, a 9.0% gain over the last 30 days, and longer term returns of 19.3% year to date and 40.5% over the last year. Recent coverage has focused on Recursion's position in biotechnology and how investor sentiment responds to updates on its platform and...
NYSE:LRN
NYSE:LRNConsumer Services

Stride (LRN) Is Down 5.1% After Narrowing 2026 Guidance And Highlighting Career Learning Strength

In late April 2026, Stride, Inc. reported third-quarter sales of US$629.87 million and net income of US$88.53 million, while narrowing full-year revenue guidance to US$2.49–US$2.52 billion and projecting income from operations of US$443–US$450 million. The results underscored continued strength in Career Learning and management’s emphasis on long-term student outcomes, even as General Education enrollment eased due to tighter enrollment policies. We’ll now examine how Stride’s narrowed...
NasdaqGS:PRDO
NasdaqGS:PRDOConsumer Services

Vanguard Stake In Perdoceo Highlights Valuation Gap And Mixed Ownership Signals

Vanguard Capital Management has disclosed beneficial ownership of more than 5% of Perdoceo Education's common stock, NasdaqGS:PRDO. The filing indicates a new significant institutional position in the company. Perdoceo Education, NasdaqGS:PRDO, operates in the postsecondary education space, providing career focused programs through its schools and online platforms. Investors watching the education sector often pay close attention to changes in institutional ownership because it can...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed?

Structure Therapeutics previously reported encouraging Phase 2 ACCESS II trial results for its oral GLP-1 receptor agonist aleniglipron, showing up to 16.3% weight reduction in adults with obesity and outlining plans to meet the FDA in Q2 2026 ahead of Phase 3 trials in the second half of 2026. The data position aleniglipron as one of the most effective oral GLP-1 candidates so far, highlighting a potentially meaningful differentiation versus other pill-based obesity treatments. Next, we...
NYSE:NEU
NYSE:NEUChemicals

Softer Q1 Results and Cash Returns Could Be A Game Changer For NewMarket (NEU)

NewMarket Corporation recently reported first-quarter 2026 results showing sales of US$669.72 million and net income of US$118.07 million, both lower than a year earlier, and its board declared a US$3.00 per-share dividend payable on July 1, 2026 to shareholders of record on June 15, 2026. Alongside these results, NewMarket completed a share repurchase of 337,201 shares for US$197.36 million, reducing its share count while continuing to return cash through dividends. We’ll now examine how...
NYSE:AAMI
NYSE:AAMICapital Markets

Is It Too Late To Consider Acadian Asset Management (AAMI) After Its 1-Year Surge?

If you are wondering whether Acadian Asset Management is still attractively priced after a strong run, the starting point is understanding what the current market price is implying about the business. The stock closed at US$65.49, with recent returns of 18.5% over 30 days, 38.2% year to date, and 135.9% over 1 year, although the last 7 days showed a 3.4% decline. Recent coverage has focused on Acadian Asset Management's share price performance and how investors are reacting to changing...
NasdaqGS:VISN
NasdaqGS:VISNCommunications

Has Vistance Networks (VISN) Pullback Opened A Fresh Opportunity For Investors?

If you are wondering whether Vistance Networks at US$11.93 is still priced attractively after a big run, the current setup gives you a lot to weigh up before making any moves. The stock has pulled back sharply in the short term, with a 38.5% decline over 7 days and a 36.3% decline over 30 days, even after very strong 413.6% 1 year and 411.5% 3 year returns. These swings have brought the stock back into focus for valuation minded investors who are weighing up whether the recent weakness is a...